The Real Gap in All of Us Isn’t Consent, It’s Conversion
Why more than 300,000 missing patient records reveal an engineering problem, not a policy one — and why that's good news.
Why more than 300,000 missing patient records reveal an engineering problem, not a policy one — and why that's good news.
The Centers for Medicare & Medicaid Services (CMS) took constructive steps in its 2027 final rule and rate announcement, particularly on payment integrity and quality measurement. But those steps are not the finish line. Policymakers should further modernize MA to strengthen competition, transparency and accountability. Here’s where to start.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
A deadline many are not tracking is October 1, 2026. It’s the day federal Medicaid funding ends for refugees, asylees, and humanitarian parolees.
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is that not only is this terrible for patient health, it can be more costly in the end.
If we want more nurses, we need more nursing students, which means creating the educational infrastructure needed to help them succeed.
To truly deliver on the promise of proactive, preventive care for seniors with complex, chronic conditions, we should move away from the current one-year open enrollment cycle and toward a five-year contract period.
The July 1 changes are being framed as student loan policy. But they raise a larger question about what kind of labor, and whose labor, America is willing to invest in.
We aren't killing the problem that fax created. We are migrating it into a format that carries a higher expectation of automated processing — without yet having solved the underlying challenge that made automation hard in the first place.
For seniors, the change in policy will dramatically expand access to a revolutionary medication. But there are also significant risks.
This is not an abstract discussion. It is about sustaining the organizations, employees, and communities that depend on us. If we fail to account for how these policies interact in the real world, we risk weakening the very system we are trying to improve.
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
Today’s adjustment offers insight into what the next phase of the program is focusing on and will subsequently reward, and why this moment matters, especially for newer and regional plans.
Consumers are inundated with false information circulating online about GLP-1 medicines, which causes confusion and can lead to potentially serious health problems resulting from dosing errors and adverse reactions to ingredients in compounded GLP-1 products.
An algorithm can flag an irregular heartbeat. But it cannot notice that Tom hasn't mentioned his late wife in two weeks, or that he's wearing the same shirt for the fourth day running. Those observations require a person in the room, not a sensor on the wall.
For consumers and clinicians the difference between “FDA-cleared,” “FDA-registered,” and general wellness products is not always obvious. Clear communication about intended use and supporting evidence is essential for maintaining trust.
Technology alone won’t solve prior authorization. But refusing to adopt it guarantees the status quo: a system where insurers operate at machine speed, providers operate at human speed, and patients pay the price in delayed care.